FindTrial
Sign In

Effect of dienogest on ovary iron deposits and ovarian function of ovarian endometriosis cyst

Effect of dienogest on ovary iron deposits and ovarian function of ovarian endometriosis cyst

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300073027
Enrollment
Unknown
Registered
2023-06-29
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

observation group (dienogest,DNG, 2mg qd po):None

Sponsors

Medical Integration and Practice Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Women aged 18-50 years old. 2.Women diagnosed as ovarian endometriosis that are treated by dienogest. 3.No hormones and gonadotropin-releasing hormone analogues (GnRH-a) were taken in the past three months. 4.Patients were informed and signed the informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: 1.Patients with contraindication to MRI examination. 2.Patients who are pregnant or lactating. 3.Patients with endocrine system disease or any other disease that may interfere with the results.

Design outcomes

Primary

MeasureTime frame
R2* value;anti-Müllerianhormone;—

Secondary

MeasureTime frame
Carbohydrate antigen 125;Visual analogue scales;—

Countries

China

Contacts

Public ContactGuoyun Wang

Shandong Provincial Hospital

wangguoy@sdu.edu.cn+86 185 6008 1729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026